Levofloxacin only — Competitive Intelligence Brief

Levofloxacin only (Levofloxacin only) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone antibiotic. Area: Infectious Disease.

phase 2 Fluoroquinolone antibiotic DNA gyrase and topoisomerase IV Infectious Disease Small molecule

Target snapshot

Levofloxacin only (Levofloxacin only) — Innocoll. Inhibits DNA gyrase and topoisomerase IV

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levofloxacin only TARGET	Levofloxacin only	Innocoll	phase 2	Fluoroquinolone antibiotic	DNA gyrase and topoisomerase IV
levofloxacin-based triple therapy	levofloxacin-based triple therapy	National Taiwan University Hospital	marketed	Fluoroquinolone antibiotic (in combination therapy)	Bacterial DNA gyrase and topoisomerase IV
β-lactams or ciprofloxacin	β-lactams or ciprofloxacin	University of Athens	marketed	Antibiotic (β-lactam and fluoroquinolone)	Penicillin-binding proteins (β-lactams); DNA gyrase and topoisomerase IV (ciprofloxacin)
Gatifloxacin 0.3%	Gatifloxacin 0.3%	Innovative Medical	marketed	Fluoroquinolone	DNA gyrase and topoisomerase IV
Experimental: Active "I-Reconstruction" Therapy	Experimental: Active "I-Reconstruction" Therapy	International Association Psychosomatics And Health Therapy	marketed	Fluoroquinolone	DNA gyrase and topoisomerase IV
Third generation fluoroquinolone	Third generation fluoroquinolone	University of Roma La Sapienza	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Intracameral Moxifloxacin 0.1%	Intracameral Moxifloxacin 0.1%	Suzan A Rattan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone antibiotic class)

1. Bayer · 4 drugs in this class
2. Allergan · 4 drugs in this class
3. Mackay Memorial Hospital · 2 drugs in this class
4. Indiana University School of Medicine · 2 drugs in this class
5. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
6. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
7. Connect Biopharma Australia Pty Ltd · 1 drug in this class
8. GlaxoSmithKline · 1 drug in this class
9. Global Alliance for TB Drug Development · 1 drug in this class
10. Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class